Ashvattha Therapeutics to Participate in Upcoming Ophthalmology Conferences

REDWOOD CITY, Calif., November 20, 2023 – Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target activated cells in regions of inflammation, today announced that members of its senior management team will participate in two upcoming ophthalmology conferences. Conference Details: BTIG 3rd Annual Ophthalmology Day  … Read more

Ashvattha Therapeutics Announces First Patient Dosed via Subcutaneous Administration of Anti-Angiogenic Therapeutic D-4517.2 for Wet AMD and DME in Phase 2 Chronic Dosing Study

Open-label study will evaluate the safety and efficacy of chronic D-4517.2 dosing in patients with wet age-related macular degeneration (wet AMD) or diabetic macular edema (DME) Favorable safety and tolerability results from Phase 1 and Phase 2 single dose studies of D-4517.2 support initiation of chronic dosing study Preliminary data expected in 1H 2024   … Read more